The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic cancer, released a statement today following positive overall survival results from Revolution Medicines’ global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated.

“We are standing at the threshold of groundbreaking treatments for patients with pancreatic cancer,” said Anna Berkenblit, M.D., MMSc, Chief Scientific and Medical Officer, PanCAN. “In the RASolute 302 trial, patients with previously treated metastatic pancreatic cancer who received a pill called daraxonrasib lived approximately twice as long as patients who received standard of care intravenous chemotherapy, a truly remarkable result in this devastating disease.

“Patients who took daraxonrasib lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy. Prior studies with daraxonrasib have shown that rash is the most common side effect, with mouth sores, diarrhea, nausea and vomiting also common.

“These results expand the potential benefit of targeted therapies to almost all patients with pancreatic cancer, as RAS mutations are detected in over 90% of pancreatic cancers and targeted therapies addressing other less common mutations are already available. Today’s announcement from Revolution Medicines represents a real opportunity to bring new hope for people facing this disease: hope for more time with family, hope for better quality of life and hope that ongoing and future research may ultimately lead to a cure. We look forward to reviewing detailed results at the American Society for Clinical Oncology (ASCO) Annual Meeting and are hopeful that the FDA commissioner’s priority voucher program allows for a rapid review.

“We thank Revolution Medicines for their commitment to science and are especially grateful to the patients who participated in the clinical trial. While these results represent a huge step forward in the field, they are just the beginning. We know that resistance to treatment can develop, and research into drug combinations is needed to overcome these challenges. Clinical trials remain the best way to advance the field and discover new breakthroughs. Daraxonrasib is the most advanced RAS inhibitor in development for pancreatic cancer, with many others being studied as well, as single agents and in combinations. And as RASolute 302 was in patients with previously treated pancreatic cancer, we are excited about the prospect of moving RAS inhibitors into earlier treatment settings.”

Pancreatic cancer is one of the most difficult cancers to detect and treat. It is the third leading cause of cancer-related deaths in the United States and is on track to become the second. With a five-year survival rate of only 13%, it remains the only major cancer whose survival rate is below 20%. Because symptoms are often vague and mimic other conditions, most patients are diagnosed in the later stages, when tumors are inoperable and treatment options are limited. Detecting the disease earlier, when surgery is possible, is critical to improving outcomes. There is no standard screening strategy for pancreatic cancer and few treatment options, highlighting the urgent need for increased funding and awareness to improve patient outcomes.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN) is the leading organization dedicated to advancing progress against pancreatic cancer. We unite the pancreatic cancer community and push every boundary to create a world where survival is the expectation — not the exception. PanCAN empowers patients and caregivers with the resources and knowledge they need to advocate for the care they deserve. We are pioneering the advancement of an early detection strategy for pancreatic cancer and revolutionizing the development of advanced and personalized treatments; and we are building and mobilizing the pancreatic cancer field to ensure better outcomes for all those who face pancreatic cancer today and all those who will fight this disease tomorrow.

For more information, please contact:
Julie Vasquez, Senior Director, Public Relations, 310-697-9129, jvasquez@pancan.org
Charaighn Sesock, Associate Director, Public Relations, 559-972-4877, csesock@pancan.org